Natera (NTRA) is back in focus after unveiling extensive Prospera transplant data at the 2026 ISHLT meeting, where 17 abstracts highlighted predictive power versus biopsies and real world impact on physician decision-making.

The latest Prospera transplant data arrive as Natera’s share price sits at US$200.17, with a 1 month share price return of 9.59% but a 3 month share price decline of 15.16%. The 1 year total shareholder return of 29.23% and 3 year total shareholder return of almost 3x suggest longer term momentum has been much stronger than the recent pullback.

If you want to see how other healthcare names using advanced diagnostics and AI are trading, it is a good time to review our screener of 32 healthcare AI stocks

With Prospera’s data in the spotlight, Natera now trades at US$200.17, following a strong 1-year run and nearly 3x total return over 3 years. Is the stock still undervalued, or is the market already pricing in future growth?

Most Popular Narrative: 22.7% Undervalued

On the most followed narrative, Natera’s fair value of $259.11 sits well above the last close at $200.17, framing a sizeable implied upside that rests heavily on future execution.

Increasing adoption and acceptance of advanced molecular diagnostics is driving sustained volume and revenue growth across Natera's diversified portfolio, with significant headroom remaining for further penetration, particularly in oncology (Signatera) and organ health (Prospera); this will likely boost top-line revenue.

Want to see what kind of revenue curve and margin lift this narrative is baking in? The fair value leans on compounding growth, rising profitability and a punchy earnings multiple that is usually reserved for market favorites.

Result: Fair Value of $259.11 (UNDERVALUED)

However, heavy R&D and commercial spend, plus the risk that trials or reimbursement decisions disappoint, could quickly weaken the bullish case embedded in that 22.7% discount.

Next Steps

The bullish tone of this narrative is clear, so this may be a good time to review the numbers yourself and stress test the story. To see what investors view as the main upsides, check the 3 key rewards

Looking for more investment ideas?

If you only focus on one stock, you risk missing opportunities elsewhere. Use the Simply Wall St screener to quickly spot ideas that fit your style.

• Target growth potential by scanning screener containing 25 high quality undiscovered gems that the wider market may not be focused on yet.
• Prioritize resilience by reviewing 72 resilient stocks with low risk scores that score well on stability and downside protection.
• Focus on financial strength by checking the solid balance sheet and fundamentals stocks screener (44 results) for companies with support from their cash flows and balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.